Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Three different mutations in the DNA topoisomerase 1B in Leishmania infantum contribute to resistance to antitumor drug topotecan.

Parasites & vectors - 28 Aug 2021

Rosa-Teijeiro Chloé, Wagner Victoria, Corbeil Audrey, d'Annessa Ilda, Leprohon Philippe, do Monte-Neto Rubens L, Fernandez-Prada Christopher

Abstract excerpt

BACKGROUND: The evolution of drug resistance is one of the biggest challenges in leishmaniasis and has prompted the need for new antileishmanial drugs. Repurposing of approved drugs is a faster and very attractive strategy that is gaining supporters worldwide. Different anticancer topoisomerase 1B (TOP1B) inhibitors have shown strong antileishmanial activity and promising selective indices, supporting the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiprotozoal Agents
Share to DNA Topoisomerases, Type I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Repositioning

Share to Leishmania infantum

Share to Leishmaniasis

Share to Molecular Dynamics Simulation

Share to Topoisomerase I Inhibitors

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 34454601
DOI: 10.1186/s13071-021-04947-4
PMCID: PMC8399852

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Three different mutations in the DNA topoisomerase 1B in Leishmania infantum contribute to resistance to antitumor drug topotecan.PMID 34454601Read ↗

Unravelling drug resistance in leishmaniasis: genomic adaptations and emerging therapiesSemantic proximity Read ↗

RES-Seq—a barcoded library of drug-resistant Leishmania donovani allowing rapid assessment of cross-resistance and relative fitnessSemantic proximity Read ↗

Genomic and phenotypic characterization of experimentally selected resistant <i>Leishmania donovani</i> reveals a role for dynamin-1 like protein in the mechanism of resistance to a novel anti-leishmanial compoundSemantic proximity Read ↗

(Post-) Genomic approaches to tackle drug resistance in Leishmania.Semantic proximity Read ↗

Drug resistance analysis by next generation sequencing in Leishmania.Semantic proximity Read ↗

Insights on genomic profiles of drug resistance and virulence in a cohort of <i>Leishmania infantum</i> isolates from the Mediterranean areaSemantic proximity Read ↗

Molecular Mechanisms of Drug Resistance in Leishmania spp.Semantic proximity Read ↗

Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.Semantic proximity Read ↗

Mutations in an Aquaglyceroporin as a Proven Marker of Antimony Clinical Resistance in the Parasite Leishmania donovani.Semantic proximity Read ↗

Epidemiological Insights: Unraveling Drug Resistance in Leishmania Species through Comprehensive StudiesSemantic proximity Read ↗

Understanding drug resistance in malaria parasites: Basic science for public healthSemantic proximity Read ↗

Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.